title: Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
abstract: Clinical efficacy, safety and pharmacokinetic properties of the high-purity double-virus inactivated plasma-derived factor VIII concentrate Haemoctin SDH (pdFVIII) were evaluated in three prospective open-label uncontrolled studies in previously treated patients (PTPs) with severe haemophilia A. The pharmacokinetic properties assessed at baseline and after 3 months of treatment are in accurate accordance with published data and remain unchanged over time (study A, n = 12). Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively. Long-term efficacy and safety, in particular the potential immunogenicity, were investigated in a total of 53 PTPs (studies A and B) treated prophylactically and on-demand, as required. PdFVIII has shown to be effective in preventing and controlling bleeding episodes; 23.5% of patients were free of bleeding events. A total of 177 haemorrhages occurred with 74.0% resolving after a single infusion, 87.6% within two infusions. 98.3% of responses reported on haemorrhages were rated as 'excellent' or 'good'. Moreover, 'excellent' haemostatic efficacy has been demonstrated in 10 surgical procedures including general and severe orthopaedic interventions (study C). No complication occurred in any surgery. Few adverse events were reported, one patient developed a high-titre FVIII inhibitor without clinical relevance. In all three studies, over 6 million units were administered in nearly 4300 infusions, approximately 94% units or infusions were given for prophylaxis and only 6% for treatment on-demand. In conclusion, pdFVIII has shown to be effective, safe and well tolerated in long-term prophylaxis and treatment on-demand as well as after minor and major surgical procedures.
authors.affiliation: Biotest Pharma GmbH, Dreieich, Germany. daniele_wolf@biotest.de
authors.forename: D M
authors.initials: DM
authors.lastname: Wolf
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: S
authors.initials: S
authors.lastname: Lopaciuk
authors.forename: A B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: A
authors.initials: A
authors.lastname: Klukowska
authors.forename: P
authors.initials: P
authors.lastname: Laguna
authors.forename: J
authors.initials: J
authors.lastname: Windyga
authors.forename: R
authors.initials: R
authors.lastname: Kotitschke
authors.forename: W G
authors.initials: WG
authors.lastname: Struff
mesh_terms: D000293:Adolescent; D000906:Antibodies / Q000032:analysis; D002648:Child; D005169:Factor VIII / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006487:Hemostasis; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D005169:Factor VIII